Home › Five Prime Therapeutics: Ridiculously Undervalued
 

Keywords :   


Five Prime Therapeutics: Ridiculously Undervalued

2015-10-17 20:45:28| Biotech - Topix.net

Five Prime trades at a ridiculously low enterprise value of ~ $280 Million after a $1.74 Billion deal with Bristol Myers Squibb. Five Prime is sitting on ~$520 Million in cash and still has a highly effective discovery platform and wholly owned assets.

Tags: prime therapeutics undervalued

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
17.05Union forming stalled in US Mercedes-Benz
17.05Johnson & Johnson Acquires Atopic Dermatitis Treatment Biotech Company
17.05Register For Sustainable Cosmetics Summit
17.05Fewer crackers in Ritz boxes but price remains same
17.05Eastern North Pacific Tropical Weather Outlook
17.05Boeing boss's $33m pay package approved
17.05Heifers and female cows remain hot topic at sale barn
17.05Dutch Boy Paints Introduces Professional Series at Menards
More »